Skip to search formSkip to main content

AVE 1330A

Known as: AVE-1330A, AVE1330A 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AzepinesSulfuric Acid Estersbeta-Lactamase Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections.
OBJECTIVE To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety… Expand
Is this relevant?
Review
2014
Review
2014
Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections
Avibactam (NXL104, AVE1330A) is a semi-synthetic, non-β-lactam, β-lactamase inhibitor that is active against Ambler class A… Expand
  • figure 1
  • figure 2
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2013
Review
2013
Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 3
Is this relevant?
2004
2004
In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.
OBJECTIVES Production of beta-lactamases is the main mechanism of beta-lactam resistance in Gram-negative bacteria. Despite the… Expand
Is this relevant?